Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Matthew Hendrich

Vascular Surgery Jonesboro, AR Medical Doctor

NPI 1528220639 CMS profile 1382867

201 E Oak Ave, Jonesboro, AR 72401

Open in the dashboard

General payments

$40,787

193 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Matthew Hendrich of Jonesboro, AR is reported in the CMS Open Payments database as having received $40,787 across 193 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,970 56
2024 General $10,356 45
2023 General $7,060 26
2022 General $8,204 23
2021 General $554 11
2020 General $1,396 7
2019 General $2,247 25

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Matthew Hendrich
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Matthew Hendrich were reported at $10,970. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Matthew Hendrich Vascular Surgery median Middle half National median
2019 $2,247 $796 $226–$2,363 $163
2020 $1,396 $348 $118–$1,110 $114
2021 $554 $471 $158–$1,421 $132
2022 $8,204 $725 $222–$2,183 $149
2023 $7,060 $836 $257–$2,440 $160
2024 $10,356 $909 $252–$2,619 $164
2025 $10,970 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Silk Road Medical, Inc. $21,152 47 payments
  2. Endologix, Inc. $8,432 30 payments
  3. Boston Scientific Corporation $8,225 29 payments
  4. W. L. Gore & Associates, Inc. $989 33 payments
  5. CVRx, Inc. $449 8 payments
  6. Haemonetics Corporation $252 2 payments
  7. Abbott Laboratories $244 6 payments
  8. Cook Medical LLC $171 5 payments
  9. Medtronic, Inc. $153 5 payments
  10. Stryker Corporation $115 4 payments
  11. Other $603 24 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $14,543 180 payments
  2. Consulting Fee $12,250 4 payments
  3. Compensation for serving as faculty or as a speaker for a medical education program $6,300 1 payment
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $5,350 2 payments
  5. Travel and Lodging $2,344 6 payments
Products named General payments · program years 2019–2025
  1. ENROUTE Transcarotid Stent $21,152 47 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $21,152 47 payments
  3. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $7,564 19 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $7,564 19 payments
  5. ENROUTE Transcarotid Neuroprotection System Enroute Nps Angle US - Pi $5,393 3 payments
  6. Alto Abdominal Stent Graft System $3,426 12 payments
  7. Ovation $2,665 11 payments
  8. General - Therapies $1,953 5 payments
  9. AFX $1,833 7 payments
  10. ENDOCROSS Device $1,093 1 payment
  11. Other $5,875 119 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

1,338

Median for Vascular Surgery: 122

Drug cost

$119,733

Median for Vascular Surgery: $14,135

Branded share of claims

67.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 111 $65,119
Brilinta Ticagrelor Brand 68 $33,538
Xarelto Rivaroxaban Brand 22 $14,284
Clopidogrel Clopidogrel Bisulfate Brand 644 $4,330
Atorvastatin Calcium Generic 127 $663
Cilostazol Generic 33 $443
Amlodipine Besylate Generic 44 $324
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 64 $271
Lisinopril Generic 29 $141
Mupirocin Generic 16 $119

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 79 billing codes

Paid by Medicare

$163,923

Medicare's payments for the services billed

Medicare patients

511

Average age 74

Services billed

1,103

227 women, 284 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 57%
Arthritis 55%
Diabetes 51%
Chronic kidney disease 39%
Heart failure 35%
Atrial fibrillation 35%
COPD 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

193 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record